Maintenance notice: Some features that submit or update information are temporarily disabled while we migrate the website. You can continue browsing normally. Thank you for your understanding.
The prescribing of selective serotonin reuptake inhibitors (SSRIs) for nonpsychiatric disorders has climbed steadily in recent years, and the June 2013 FDA approval of paroxetine to treat hot flashes associated with menopause is likely to expose more women to this popular class of antidepressants.
A new observational, claims-based analysis found that 137,000 women between the ages of 40 and 64 without mental illness who started an SSRI between 1998 and 2010 were 67% to 76% more likely to break a bone during the subsequent one to five years than 236,000 women of the same age who took indigestion drugs during the same time period.
If you have orthopedic information that you would like to share with the Orthogate Community, please register/login and submit your news, event, job, article, case or workshop from the Submit Content menu under the My Account area. Learn more!
Improving orthopaedic care, education and research using Internet technologies